Travis J. Hollmann

Travis J. Hollmann

Auto-generated profile, based on publicly available information

Travis J. Hollmann

Memorial Sloan Kettering Cancer Center

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ASAlexandra Snyder
Alexandra Snyder
VMVladimir Makarov
Vladimir Makarov
TMTaha Merghoub
Taha Merghoub
JYJianda Yuan
Jianda Yuan
JZJesse M. Zaretsky
Jesse M. Zaretsky
TCTimothy A. Chan
Timothy A. Chan
Immune checkpoint inhibitors are effective cancer treatments, but molecular determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4). Anti–CTLA-4 treatment prolongs overall survival in patients with melanoma. CTLA-4 blockade activates T cells and enables them to destroy tumor cells. We obtained tumor tissue from patients with melanoma who were treated with ipilimumab or tremelimumab. Whole-exome sequencing was performed on tumors and matched blood samples. Somatic mutations and candidate neoantigens generated from these mutations were characterized. Neoantigen peptides were tested for the ability to activate lymphocytes from ipilimumab-treated patients. Malignant melanoma exomes from 64 patients treated with CTLA-4 blockade were characterized with the use of massively parallel sequencing. A discovery set consisted of 11 patients who derived a long-term clinical benefit and 14 patients who derived a minimal benefit or no benefit. Mutational load was associated with the degree of clinical benefit (P=0.01) but alone was not sufficient to predict benefit. Using genomewide somatic neoepitope analysis and patient-specific HLA typing, we identified candidate tumor neoantigens for each patient. We elucidated a neoantigen landscape that is specifically present in tumors with a strong response to CTLA-4 blockade. We validated this signature in a second set of 39 patients with melanoma who were treated with anti–CTLA-4 antibodies. Predicted neoantigens activated T cells from the patients treated with ipilimumab. These findings define a genetic basis for benefit from CTLA-4 blockade in melanoma and provide a rationale for examining exomes of patients for whom anti–CTLA-4 agents are being considered. (Funded by the Frederick Adler Fund and others.)

18 November 2021 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
NGNoah F. Greenwald
Noah F. Greenwald
GMGeneva Miller
Geneva Miller
EMErick Moen
Erick Moen
AKAlex Kong
Alex Kong
AKAdam Kagel
Adam Kagel
DVDavid Van Valen
David Van Valen

29 August 2022 in Nature Cancer
Verified
Journal Article
Open access
PDF file
RVRami S. Vanguri
Rami S. Vanguri
JLJia Luo
Jia Luo
AAAndrew T. Aukerman
Andrew T. Aukerman
JEJacklynn V. Egger
Jacklynn V. Egger
CFChristopher J. Fong
Christopher J. Fong
SSSohrab P. Shah
Sohrab P. Shah
Immunotherapy is used to treat almost all patients with advanced non-small cell lung cancer (NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we show the predictive capacity of integrating medical imaging, histopathologic and genomic features to predict immunotherapy response using a cohort of 247 patients with advanced NSCLC with multimodal baseline data obtained during diagnostic clinical workup, including computed tomography scan images, digitized programmed death ligand-1 immunohistochemistry slides and known outcomes to immunotherapy. Using domain expert annotations, we developed a computational workflow to extract patient-level features and used a machine-learning approach to integrate multimodal features into a risk prediction model. Our multimodal model (area under the curve (AUC) = 0.80, 95% confidence interval (CI) 0.74–0.86) outperformed unimodal measures, including tumor mutational burden (AUC = 0.61, 95% CI 0.52–0.70) and programmed death ligand-1 immunohistochemistry score (AUC = 0.73, 95% CI 0.65–0.81). Our study therefore provides a quantitative rationale for using multimodal features to improve prediction of immunotherapy response in patients with NSCLC using expert-guided machine learning.

3 June 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
LPLacey J. Padrón
Lacey J. Padrón
DMDeena M. Maurer
Deena M. Maurer
MOMark H. O’hAra
Mark H. O’hAra
Eileen O'ReillyEileen O'Reilly
Eileen O'Reilly
RWRobert A. Wolff
Robert A. Wolff
RVRobert H. Vonderheide
Robert H. Vonderheide
Chemotherapy combined with immunotherapy has improved the treatment of certain solid tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma (PDAC). We conducted a randomized phase 2 trial evaluating the efficacy of nivolumab (nivo; anti-PD-1) and/or sotigalimab (sotiga; CD40 agonistic antibody) with gemcitabine/nab-paclitaxel (chemotherapy) in patients with first-line metastatic PDAC (NCT03214250). In 105 patients analyzed for efficacy, the primary endpoint of 1-year overall survival (OS) was met for nivo/chemo (57.7%, P = 0.006 compared to historical 1-year OS of 35%, n = 34) but was not met for sotiga/chemo (48.1%, P = 0.062, n = 36) or sotiga/nivo/chemo (41.3%, P = 0.223, n = 35). Secondary endpoints were progression-free survival, objective response rate, disease control rate, duration of response and safety. Treatment-related adverse event rates were similar across arms. Multi-omic circulating and tumor biomarker analyses identified distinct immune signatures associated with survival for nivo/chemo and sotiga/chemo. Survival after nivo/chemo correlated with a less suppressive tumor microenvironment and higher numbers of activated, antigen-experienced circulating T cells at baseline. Survival after sotiga/chemo correlated with greater intratumoral CD4 T cell infiltration and circulating differentiated CD4 T cells and antigen-presenting cells. A patient subset benefitting from sotiga/nivo/chemo was not identified. Collectively, these analyses suggest potential treatment-specific correlates of efficacy and may enable biomarker-selected patient populations in subsequent PDAC chemoimmunotherapy trials.

14 December 2022 in Nature
Verified
Journal Article
Open access
PDF file
IVIgnacio Vázquez-García
Ignacio Vázquez-García
FUFlorian Uhlitz
Florian Uhlitz
NCNicholas Ceglia
Nicholas Ceglia
JLJamie L. P. Lim
Jamie L. P. Lim
MWMichelle Wu
Michelle Wu
SSSohrab P. Shah
Sohrab P. Shah
High-grade serous ovarian cancer (HGSOC) is an archetypal cancer of genomic instability1–4 patterned by distinct mutational processes5,6, tumour heterogeneity7–9 and intraperitoneal spread7,8,10. Immunotherapies have had limited efficacy in HGSOC11–13, highlighting an unmet need to assess how mutational processes and the anatomical sites of tumour foci determine the immunological states of the tumour microenvironment. Here we carried out an integrative analysis of whole-genome sequencing, single-cell RNA sequencing, digital histopathology and multiplexed immunofluorescence of 160 tumour sites from 42 treatment-naive patients with HGSOC. Homologous recombination-deficient HRD-Dup (BRCA1 mutant-like) and HRD-Del (BRCA2 mutant-like) tumours harboured inflammatory signalling and ongoing immunoediting, reflected in loss of HLA diversity and tumour infiltration with highly differentiated dysfunctional CD8+ T cells. By contrast, foldback-inversion-bearing tumours exhibited elevated immunosuppressive TGFβ signalling and immune exclusion, with predominantly naive/stem-like and memory T cells. Phenotypic state associations were specific to anatomical sites, highlighting compositional, topological and functional differences between adnexal tumours and distal peritoneal foci. Our findings implicate anatomical sites and mutational processes as determinants of evolutionary phenotypic divergence and immune resistance mechanisms in HGSOC. Our study provides a multi-omic cellular phenotype data substrate from which to develop and interpret future personalized immunotherapeutic approaches and early detection research.

7 October 2015 in Nature
Verified
Journal Article
Closed access
PDF file
TWThomas Wiesner
Thomas Wiesner
WLWilliam Lee
William Lee
AOAnna C. Obenauf
Anna C. Obenauf
LRLeili Ran
Leili Ran
RMRajmohan Murali
Rajmohan Murali
PCPing Chi
Ping Chi